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ABSTRACT
It is well established that the cytokine IL-12 and the
transcription factor STAT4, an essential part of the IL-12
signaling pathway, are critical components of the Th1
differentiation process in T cells. In response to pathogenic
stimuli, this process causes T cells to proliferate rapidly and
secrete high amounts of the cytokine IFN-g, leading to the
Th1 proinflammatory phenotype. However, there are still
unknown components of this differentiation pathway. We
here demonstrated that the expression of the histone
methyltransferase Mll1 is driven by IL-12 signaling through
STAT4 in humans and mice and is critical for the proper
differentiation of a naı̈ve T cell to a Th1 cell. OnceMLL1 is up-
regulated by IL-12, it regulates the proliferation of Th1 cells.
As evidence of this, we show that Th1 cells fromMll1+/2 mice
are unable to proliferate rapidly in a Th1 environment in vitro
and in vivo. Additionally, upon restimulation with cognate
antigenMll1+/2, T cells do not convert to a Th1 phenotype, as
characterized by IFN-g output. Furthermore, we observed
a reduction in IFN-g production and proliferation in human
peripheral blood stimulated with tetanus toxoid by use of
a specific inhibitor of the MLL1/menin complex. Together,
our results demonstrate that the MLL1 gene plays a
previously unrecognized but essential role in Th1 cell
biologyand furthermore, describesanovel pathway through
which Mll1 expression is regulated. J. Leukoc. Biol.
98: 601–613; 2015.
Introduction
The local host cytokine response to external stimuli dictates the
type of innate- and adaptive-immune responses that subsequently
occur. Many of the cytokine signals received by cells are
transmitted into the nucleus via STAT proteins. As a classic
example, production of IL-12 during the innate-immune re-
sponse causes CD4+ T cells to skew toward a proinflammatory
Th1 phenotype, characterized by production of IFN-g and
expression of the transcription factor T-bet. In contrast, exposure
of CD4+ T cells to IL-4 skews them toward an alternative Th2
phenotype characterized by the production of the cytokines IL-4,
IL-5, and IL-13 and expression of the transcription factor
GATA3. In both cases, the particular cytokine milieu is also
responsible for developing the T cell recall response. Thus, mice
deficient in the STAT6/IL-4 or the STAT4/IL-12 signaling
pathway have aberrant T cell memory responses [1–3]. STAT4
phosphorylation by JAK proteins results in its migration to the
nucleus, where it functions as a transcription factor for IL-12.
Likewise, STAT6 phosphorylation by JAK causes the expression
of IL-4. For IL-12 and IL-4, the respective STAT proteins act as
transcription factors upon phosphorylation by JAK proteins.
Once in the nucleus, STAT promotes the expression of target
genes that are important for T cell differentiation and function.
In Th1 cells, these genes include Ifng, Il18r1, Irf1, and Irf4 [4–6].
Some of these STAT target genes are involved in cell pro-
liferation [7], an important feature of effector and memory T cell
subsets. For example, STAT5 is known to induce the expression
of Ccnd1 and Ccnd2, 2 genes critical for the proliferation
of lymphocytes [8, 9]. Although it has been demonstrated that
IL-12-driven proliferation through STAT4 is essential to proper
Th1 function, the mechanism by which this proliferation occurs
is unknown [10].
In addition to STAT4 and IL-12, the transcription factor T-bet
has been shown to be an essential regulator of a functional Th1
response [10, 11]. T-bet, a downstream target of STAT4, may
function by directly opposing the transcription factor GATA-3
instead of actively differentiating cells toward the Th1 lineage
[12]. In agreement with this, it has been demonstrated that there
are STAT4-dependent but T-bet-independent genes expressed
during Th1 differentiation [13]. Furthermore, T cells deficient in
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Tbx21, the gene for T-bet, can differentiate into Th1 cells without
difficulty under optimal conditions in vitro [12]. These studies
hint that there may be other factors controlling IL-12-induced
Th1 development that are independent of T-bet and STAT4
itself, although to date, none have been found [13, 14].
Evidence of epigenetic regulation of T cell phenotype and data
supporting that substantial chromatin modification occurs upon
differentiation exists for nearly every T cell subset [14–18].
However, in the majority of cases, the chromatin modifiers that
regulate these processes have not been identified. It is our
hypothesis that proper expression of certain chromatin-
modifying enzymes is dictated by exposing T cells to a specific
cytokine environment, thus causing T cell differentiation. These
enzymes regulate gene expression by altering chromatin
structure to a conformation that makes a particular gene
accessible or inaccessible to binding of transcription factors. We
hypothesize that up-regulation of these chromatin-modifying
enzymes in a cytokine-dependent manner is essential to the
differentiation and maintenance of the relevant T cell pheno-
type. Here, we present evidence that the chromatin-modifying
histone methyltransferase MLL1 is a previously unknown factor
involved in Th1 cell differentiation. Our data indicate that this
gene is involved in STAT4-dependent Th1 cell differentiation
and also the maintenance of the Th1 cell memory phenotype.
The Mll1 gene was originally cloned from a subset of acute
leukemia patients with cells expressing lymphoid and myeloid
markers, indicative of a transformed multipotent progenitor cell
[19]. MLL1 is a histone methyltransferase for H3K4Me, a mark
associated with transcription activation, and is cleaved into its
active form by the enzyme Taspase1 [20]. The proper function-
ing of MLL1 is dependent on interaction with other proteins
required for binding to chromatin, including the tumor
suppressor menin and the scaffold protein lens epithelium-
derived growth factor [21, 22]. Previous studies in mice have
demonstrated that the Mll1 gene is essential for embryonic
development [23], as well as differentiation in multiple cell types,
including hematopoietic stem cells [24], Th2 memory cells
[25, 26], and neural cells [27]. In addition, Mll1 function has been
shown to regulate cellular proliferation by affecting G1/S- and
M-phase cell-cycle progression in mouse fibroblasts [20, 28]. These
functions are partly achieved through MLL1-dependent regula-
tion of cyclin genes.
Although numerous studies have been done to determine how
the MLL1 protein regulates the transcription of target genes—
most notably, homeobox A9 [29]—to date, there is no data on how
the Mll1 gene itself is regulated. Here, we demonstrate that Mll1
expression is driven by IL-12 signaling, and is a critical factor for
Th1 biology that regulates T cell proliferation, an important
aspect of the T cell differentiation process [30, 31]. To examine
the interplay between Mll1 expression and the local cytokine
milieu, we used an in vivo model of a Th1 response to
mycobacterial antigens in the form of PPD. We found that in
normal T cells, the up-regulation of Mll1 by IL-12 is critical to the
proper differentiation of the Th1 lineage. Deletion of 1 Mll1
allele in mice leads to a striking defect in the formation of Th1
cells, characterized by a significant reduction in the proliferation
of Mll1+/2 CD4 T cells in vitro and in vivo. This reduced
proliferative response was correlated with a reduction in
expression of Ccnd3, a critical gene for T cell proliferation [32].
In addition Mll1+/2 CD4 T cells failed to mount an appropriate
recall response to the antigen, a finding that mirrors the studies
detailing the role of Mll1 in the Th2 response [25, 33]. To
determine if Mll1 is important in the human-recall response, we
used a specific inhibitor of the MLL1/menin complex [34] in
human T cell/DC cocultures stimulated with tetanus toxoid. We
found that this inhibitor decreased T cell proliferation and
cytokine output during the human in vitro-recall response. These
latter data represent a novel approach to controlling aberrant
T cell-driven inflammatory processes.
MATERIALS AND METHODS
Mice
Mll1+/2 mice were obtained from Dr. Yali Dou and bred as heterozygotes at
the University of Michigan. For granuloma formation, 1.0 3 105 live
Mycobacterium (BCG strain) were nonsurgically instilled intratracheally. Two
weeks later, 5000 PPD-conjugated, sized sepharose beads [35] were injected
intravenously, and mice were analyzed at day 2 or 4 postinjection. Mll1+/2
mice were used, as Mll12/2 mice are embryonically lethal.
Cell culture
Murine cell culture. Single-cell suspensions were made from whole spleens
that were then centrifuged and incubated with cold RBC lysis buffer for 1 min.
CD4 cells were then isolated by use of the CD4 isolation kit (Miltenyi Biotec,
Bergisch Gladbach, Germany), according to the manufacturer’s instructions.
Isolated cells were checked for purity by use of anti-CD4 PE/Cy7 antibody
clone RM4.5 (BioLegend, San Diego, CA, USA). Cells isolated from the
draining lymph node for coculture were isolated by the same method. Th1
cells were generated by use of anti-CD3 antibody (eBioscience, San Diego, CA,
USA), coated on plates at 3 mg/ml for 2 h at 37°C in PBS. Th0 and Th1 cells
received 3 mg/ml anti-CD28 (eBioscience). Th1 cultures also received 10 mg/ml
anti-IL-4 (eBioscience) and 10 ng/ml rIL-12 (R&D Systems, Minneapolis,
MN, USA) to abrogate IL-4 signaling caused by endogenously produced IL-4
and to promote IL-12 signaling to affect Th1 differentiation. To eliminate
effects of endogenously produced IL-12, Th0 cells also received 10 mg/ml anti-
IL-12. All cell culture was done in complete RPMI containing 10% heat-
inactivated FCS (Atlas Biologicals, Fort Collins, CO, USA) with 1% nonessential
amino acids, 1% sodium pyruvate, and 1% penicillin/streptomycin. Except for
FCS, all cell-culture reagents were purchased from Lonza (Basel, Switzerland).
For ChIP assays, 1.0 3 107 cells were cultured in 6 well plates in 1.5 ml media.
For all other assays, 1.0 3 105 cells were plated in anti-CD3 antibody-coated, 96
well, flat-bottom plates in 100 ml media. For cocultures, BMDCs were derived
from naı̈ve animals by culturing bone marrow in 10 ng/ml rGM-CSF for
10 d and harvesting nonadherent cells. T cells were cultured with DCs at a
10:1 ratio in 96 well, flat-bottom plates with 10 mg/ml PPD antigen. For all
experiments (see Fig. 6 for exceptions), T cells were analyzed at the indicated
time point, postinitial stimulation, with anti-CD3/anti-CD28 in the described
culture conditions. No additional stimulation was required to generate the
depicted readouts. Cells were stimulated for 5 d, rested for 3 d, and then
restimulated with plate-coated anti-CD3 (3 mg/ml) and soluble anti-CD28
(3 mg/ml) for 48 h (see Fig. 6A and B).
Human cell culture. Peripheral blood was isolated from normal, healthy
donors (ages 18–65), immediately diluted 1:1 with saline, and overlaid on
Ficoll (GE Healthcare, Pittsburgh, PA, USA), according to the manufac-
turer’s instructions. Blood was drawn under Institutional Review Board
HUM00075841. CD4+ cells were isolated from peripheral blood by use of
a Human CD4 Isolation Kit II from Miltenyi Biotec. For generation of Th1
cells, cells were cultured for 7 d in the presence of 50 ng/ml rhIL-12 (R&D
Systems) and 10 mg/ml anti-IL-4 (eBioscience) on plates coated with anti-
human CD3/CD28 antibody as above. Complete media were as described
above, with the substitution of 10% AB human serum (Sigma-Aldrich,
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St. Louis, MO, USA) for FCS. For cocultures with DCs, CD14+ cells were isolated
from the blood by use of Miltenyi Biotec CD14 beads before CD4+ T cell
isolation. CD14+ cells were grown in 50 ng/ml rhIL-4 and 50 ng/ml rhGM-
CSF for 7 d at a concentration of 1.0 3 106 cells/ml in complete RPMI with
FCS. Floating and loosely adherent cells were collected by washing flasks
several times with media. At this point, T cells cryopreserved on the day of
the blood draw in KM Banker II freezing media (CosmoBio, Tokyo, Japan) at
5.0 3 107/ml were thawed and cultured with DCs at a 10:1 ratio in 96 well,
flat-bottom plates with 1 mg/ml tetanus toxoid added. Cultures were
incubated for 6 d before analysis.
Proliferation
In vitro proliferation. Cells (1.0 3 105) cells were cultured in 100 ml in
a 96 well, flat-bottom plate for the indicated amount of time. [3H]Thymidine
was added at 12 h before the time point at a concentration of 0.5 mCi/well.
Samples were harvested by use of a Cambridge PHD harvester, and wells were
washed 33 with dH20. Counts were measured by use of an LS6500
scintillation counter (Beckman Coulter, Brea, CA, USA).
In vivo proliferation. Mice were injected with 100 ml of a 1 mg/ml solution
of EDU Invitrogen, Grand Island, NY, USA), 12 h before analysis. EDU
incorporation was assessed by use of the Click-iT kit, per the manufacturer’s
instructions.
ChIP
ChIP was performed by use of the Chromatin Immunoprecipitation Assay Kit
(#17-295) from Millipore (Billerica, MA, USA). Anti-STAT4 (sc-486) antibody
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
STAT1, STAT5, and STAT6 antibodies were purchased from Cell Signaling
Technology (Danvers, MA, USA). Analysis of the promoters of Ccnd3, Tbx21,
Ifng, and Il12rb2 genes was performed by use of a custom EpiTect array
purchased from Qiagen (Valencia, CA, USA). The STAT4 binding sites on the
Mll1 promoter were assessed by use of primers (Table 1).
Imaging
Fluorescence microscopy was performed with a Zeiss LSM 510 microscope and
viewed with a UV and HeNe laser. Pictures for light microscopy were taken
with an Olympus BX43 microscope with an Olympus DP73 camera.
Flow cytometry
Flow cytometry was done on an LSR II with 488, 633, and 405 nM lasers.
Antibodies to T-bet, IFN-g, CD4, CD44, CD62L, CD69, CD8, CD11b, CD11c,
Gr-1, and MHC II were purchased from BioLegend and used at a 1:200
dilution to stain between 1.0 3 104 and 1.0 3 107 cells in 200 ml FACS buffer
(containing 1% FCS and 0.002 M EDTA). Anti-IL-12RB2 antibody was
purchased from R&D Systems and used at a dilution of 1:100. For EDU
treatment, 100 ml of a 10 mg/ml solution of EDU was injected into mice, 24 h
before analysis (Invitrogen). Cells were then labeled according to the
manufacturer’s instructions. To analyze only viable cells, the LIVE/DEAD
Fixable Violet Dead Cell Stain Kit (Invitrogen) was used, according to the
manufacturer’s instructions. All cell culture and lung experiments were
analyzed by first gating on viable cells and subsequently determining
populations of interest. CFSE (Invitrogen) was used to label cells at
a concentration of 10 nM in a 5% FCS/PBS solution. Cells were incubated for
5 min at room temperature in the dark and then washed 23 with complete
media before plating [36]. For intracellular cytokine staining, cells were
incubated with a 0.05 ml GolgiStop and 0.05 ml GolgiPlug (BD Biosciences,
San Jose, CA, USA) in 100 ml media for 6 h before surface staining. Cells
were then fixed for 15 min with 5% normal-buffered formalin and washed
33 with BD Perm/Wash buffer before staining for intracellular proteins. For
lung flow cytometry, minced lungs were digested in 5 ml of a 1 mg/ml
solution of Collagenase A (Roche Diagnostics, Indianapolis, IN, USA) and 10
Kunitz units of DNAse I (Sigma-Aldrich) in complete medium for 45 min at
37°C in a shaking incubator. Samples were subsequently passed 153 through
a 5 ml syringe with an 18 G needle, filtered through 100 mM Nitex (WildCo,
Yulee, FL, USA) to remove debris, and RBCs then lysed by use of buffer
purchased from BioLegend. EDU staining was performed by use of the
AlexaFlour 488 EDU kit, according to the manufacturer’s instructions
(Invitrogen), with volumes adjusted for a 96 well plate format (total volume
of 100 ml/reaction). In vivo proliferation was measured by injection of 1 mg
EDU, dissolved in 100 ml PBS, 24 h before analysis. In vitro EDU
proliferation was measured by pulsing a 100 ml culture of cells in a 96 well
plate with 1 ml of a 10 mg/ml solution of EDU dissolved in sterile PBS (final
concentration of 100 mg/ml).
Flow cytometry for Mll1 was performed by use of Mll1 antibody NB-600-256
at 1:1000 dilution (Novus Biologicals, Littleton, CO, USA). This antibody was
conjugated directly to the Pacific Blue fluorochrome by use of an antibody
conjugation kit from Invitrogen. Before conjugation, the storage buffer of the
antibody was removed and replaced with PBS by use of Amicon Ultracel 100K
centrifugal filters (Millipore). Flow cytometry for Ccnd3 was performed by
incubating cells with ab52598 at a 1:500 dilution (Abcam, Cambridge, MA,
USA) for 20 min, followed by 2 washes with Perm/Wash Buffer. Secondary
anti-rabbit allophycocyanin (R&D Systems) was used at a dilution of 1:200 with
an incubation time of 20 min.
RNA
RNA was isolated by Trizol (Invitrogen) and reverse transcribed by use of
iScript (Bio-Rad Laboratories, Hercules, CA, USA). qPCR was performed on
an Applied Biosystems (Carlsbad, CA, USA) 7500 analyzer by use of TaqMan
reagents. All genes were normalized to gapdh to conduct DD comparative
threshold analysis.
Statistics
Statistical analysis was performed as indicated by use of Prism 6 (GraphPad
Software, La Jolla, CA, USA). Peak calling assays were performed by use of
Homer [37] and the mm9 build of the Mus musculus genome.
TABLE 1. Primers used to assess the STATS binding sites on the Mll1 promoter
Primer Human Mouse
STAT4-binding site 1 F: CGGGGCGAATGGCTCTCC F: AAATCCCTTGGCACAGAC
R: CCGGCGAGGGGGTCTGTG R: CCAGGGAAGGAGGCGGAGATG
STAT4-binding site 2 F: CGTTGCCCCTTCCCCATTAGTA F: TTCAGGTTCAGTCAATGGCTATGC
R: CGCCACTGGCTGAACCTGAACT R: CCCCTTCCCCTGCGATTCAAACT
STAT4-binding site 3 F: GAAGAAGGGTTGTGATAGGGAAGA F: ATATGGAGGGGGATTCA
R: TCAAAAGGGGAGGGAGAACCAAT R: CTAAAAGGCCACCAAGAT
Il2ra F: TGGTACTTCCTAGAAGAAACTGCT F: AAGAGGAGGCAATCTGGGTCAGATA
R: GGTCAGAAATTTGTTGTCCGC R: GGTCAACTGTATAAAGCTGAGTCTC
STAT6 Hs: Spint1 Mm: Rad50 F: GCCTTCGCTCTAGGACTGG F: CCACACACTGGGATGTGTAGCTCA
R: AACCACAGGCTTCCAAGAAA R: AGACCCAGCTCCTCAGAAGGTAGT
F, forward; Hs, Homo sapiens; Mm, Mus musculus, R, reverse.
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RESULTS
Mll1+/2 mice display altered granuloma pathology
accompanied by differences in cytokine levels in
the lung
To determine if Mll1 was important in a T cell-driven Th1
response, we infected mice with live Mycobacterium (BCG strain)
and then 14 d later, challenged them with PPD-coated beads via
intravenous tail-vein injection. Injected beads lodge in the lungs
of the mice and cause the formation of granulomas. Previous
research has indicated that 4 d postinjection is the peak
inflammatory response in WT mice. We found that 4 d was also
the peak of granuloma formation in Mll1+/2 mice; however, the
pathology associated with granulomas in Mll1+/2 was altered
significantly compared with WT mice.
The dominant response to challenge with PPD beads is IFN-g
production by CD4+ T cells [35]. Histologic examination of
granulomas revealed that WT granulomas were compact and
consisted mainly of mononuclear cells, whereas Mll1+/2 granu-
lomas consisted of large numbers of granulocytic polymorpho-
nuclear cells (Fig. 1A and B). We also observed a reduction in
IFN-g levels in the lungs of Mll1+/2 mice at the RNA and protein
level (Fig. 1C and D). The reduction in IFN-g levels in the lung
correlated with a reduction in effector CD4+ T cells, as
determined by a decrease in the number of CD4+ cells bearing
the signature of CD44hiCD62llo expression. There was no
difference in the total number of CD4+ lung or lymph node nor
in the number of CD4+ memory cells (CD44hiCD62lloCCR7+; Fig.
1F) at these sites. We also observed no difference in CD8+ T cells
or CD19+ cells in the lung or lymph node. The predominance of
granulocytes at the site of the granuloma was correlated with an
increase in lung neutrophils (Gr1hiMHC II2) in Mll1+/2 mice, as
determined by flow cytometry (Fig. 1E). There was no change in
the number of macrophages or DCs. Immunofluorescent
staining for the H3K4Me3 modification mediated by MLL1
revealed a paucity of this mark in Mll1+/2 granulomas (Fig. 1G),
thus confirming that MLL1 was nonfunctional in these mice. We
did not detect an increase in IL-17 at the protein or mRNA level
in Mll1+/2 mice nor was there increased production of IL-17
from cultures of draining lymph nodes restimulated with PPD
antigen (data not shown). To determine how Mll1 expression is
altered during T cell differentiation, we FACS-sorted naı̈ve,
effector, and memory cells from the spleens of WT mice
immunized with PPD/CFA for 14 d. We found that Mll1
expression is highest in naı̈ve and memory cells and reduced in
effector cells (Fig. 1H). To determine the level of Mll1
expression in Mll1+/2 mice, we then sorted naı̈ve and effector
cells from the lungs and lymph nodes of PPD immunized and
challenged mice. We found that Mll1 expression was not altered
in naı̈ve cells in the lung or lymph node. However, effector cells
isolated from the lungs of Mll1+/2 mice had 50% reduced Mll1
expression compared with WT controls (Fig. 1H).
Transferred Mll1+/2 CD4+ T cells recapitulate the
phenotype of Mll1+/2 mice
We next tested if CD4+ T cells are responsible for the observed
changes in granuloma pathology in Mll1+/2 mice by transferring
splenic CD4+ T cells fromMll1+/2 mice or littermate controls into
Rag22/2 mice. Recipients were then sensitized and challenged as
described above. The transfer of CD4+ T cells from Mll1+/2 mice
into Rag22/2 mice reproduced all of the features of the
granuloma, initially observed in Mll1+/2 mice. These included
reduced IFN-g in the lung (Fig. 2A), a decrease in Mll1 mRNA
expression (Fig. 2B), and an increase in granuloma size (Fig. 2C
and D). Histologic examination again revealed granulomas with
increased numbers of polymorphonuclear cells in mice receiving
Mll1+/2 T cells (Fig. 2D). Additionally, we observed an increase in
neutrophils in the lung and a decrease in total CD4 cells in the
lung (Fig. 2E and F) by flow cytometry. The decrease in total CD4
cells was likely observable because of the decreased amount of
CD4 cells present in Rag22/2 mice, which in turn amplifies the
contribution of the effector population to the total pool of
T cells. Thus, these experiments confirmed the results seen
above in Mll1+/2 mice, showing the importance of the Mll1+/+
gene to the expression of a proper Th1 phenotype.
Th1 cells undergo Mll1-dependent proliferation
The MLL1 protein has been implicated previously in the
regulation of the cell cycle and the proliferation of fibroblasts
[28]. As our data indicated a reduced number of CD4+ effector
cells in vivo after PPD immunization and challenge, we next
determined the ability of Mll1+/2 T cells to proliferate under Th1
conditions in vitro. For these experiments, we assessed the ability
of WT and Mll1+/2 CD4 T cells to incorporate [3H]thymidine
under Th0 (anti-CD3/anti-CD28 + anti-IL-12) and Th1 (anti-
CD3/anti-CD28 + anti-IL-4 + rIL-12) conditions. We found that
Mll1+/2 T cells under Th0 conditions were able to proliferate as
well as WT Th0 cells at all time points (48–120 h; data not
shown). However, under Th1 conditions, Mll1+/2 cells had
a reduced, proliferative capacity, as measured by [3H]thymidine
uptake (Fig. 3A). By calculating the ratio of Th1 proliferation
compared with Th0 proliferation, we found that IL-12-dependent
proliferation started at 72 h post-CD3 stimulation and was
greatest in WT cells at 120 h poststimulation (Fig. 3B). In Mll1+/2
Th1 cells, the ratio of proliferation fell below 1 at 72 h, indicating
that Mll1+/2 Th1 cells proliferated less than Mll1+/2 Th0 cells at
this time. The proliferative ratio between Mll1+/2 Th1 and Th0
cells continued to decrease through 120 h poststimulation. With
the use of the nucleotide analog EDU, we tested whether Mll1+/2
cells had reduced proliferation in vivo by pulsing PPD-sensitized
and -challenged Rag22/2 mice on day 3 postbead injection and
assessed the incorporation of this analog by flow cytometry, 24 h
later. As described previously, these mice received WT or Mll1+/2
T cells, 2 wk before analysis. We found a decrease in proliferation
of total CD4 T cells from Mll1+/2 mice in the lung and draining
lymph nodes (Fig. 3C).
Cells deficient in functional MLL1 protein have been shown to
have reduced expression of cell-cycle genes and an increase in
expression of select tumor-suppressor genes [20]. We next
examined the expression of a panel of genes involved in cell-
cycle progression, including family members from the A-, B-, D-,
and E-type cyclins. We observed decreased expression of Ccnd3 in
Mll1+/2 Th1 cells (Fig. 3D). There was no decrease in the
expression of other cell-cycle genes (Ccna2, -b1, -b2, -d1, -e1, -e2)
or increase in expression of tumor-suppressor genes (Cdkn1a,
Cdkn1b, Cdkn2a, Cdkn2c), as measured by qPCR (data not
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shown). We also found a reduction in Ccnd3 expression in effector
(CD44hiCD62Llo) T cells isolated from the lungs of Mll1+/2 mice at
4 d postbead injection (Fig. 3E). To determine whether Mll1+/2
cells also contained less Ccnd3 protein, we performed flow
cytometry for Ccnd3 on WT and Mll1+/2 Th1 cultures (Supple-
mental Fig. 1A). We found a reduced amount of Ccnd3+ Mll1+/2
cells at 96 and 120 h poststimulation with anti-CD3, confirming that
Mll1+/2 cells have reduced Ccnd3 at the RNA and protein level at
later time points post-CD3 activation in the presence of IL-12
(Fig. 3D–F).
Because of the critical role of IL-2 and the IL-2R CD25 in
T cell proliferation, we assessed in vitro-activated T cells for the
presence of the CD25 molecule by flow cytometry and found no
differences between Mll1+/2 cells and littermate controls in Th0
or Th1 conditions at any time point (data not shown). As an
additional test to determine if IL-2 caused the observed
reduced proliferation, we added rIL-2 to in vitro cultures and
assessed [3H]thymidine uptake at 96 h postactivation (Supple-
mental Fig. 1B). We observed an increase in proliferation in
Th0 and Th1 cultures of both genotypes when IL-2 was added
compared with no IL-2 controls. However, there was a signifi-
cant decrease in [3H]thymidine uptake in Mll1+/2 Th1 cells
compared with Th1 cells from WT littermate controls in the
presence of rIL-2 (Supplemental Fig. 1B). These data suggest
that the reduced proliferation in Mll1+/2 Th1 is at least partially
dependent on IL-2.
Figure 1. Mll1+/2 mice have an altered response to
PPD antigen challenge at 4 d post-PPD bead
challenge. (A and B) H&E staining of lungs from WT
and Mll1+/2 mice at 4 d postbead injection and
a graph quantifying significant differences in granu-
loma size. *P , 0.03, as determined by Student’s t test.
(C and D) Quantification of IFN-g at protein and
mRNA levels. (E) Analysis of infiltrating myeloid cell
populations in the lung. Results are representative of
3 separate experiments. *P , 0.007, as determined by
Student’s t test. Neutrophils [polymorphonuclear
neutrophils (PMN)] were defined as autofluorescent-
negative CD11b+CD11c2Ly6G+, DCs as autofluores-
cent-negative CD11c+CD11b+Ly6C+MHC II+, and
macrophages (MF) as autofluorescent-negative
CD11b+F/480+MHC IImidhigh. (F) Analysis of total
CD4+ T cells, as well as T cell subsets in the lung and
lymph node. Effector CD4 cells were defined as
CD44hiCD62Llo, and memory cells were defined as
CD44hiCD62L+CCR7+. *P , 0.05, as determined by
Student’s t test. (G) Staining of lung sections with
antibodies to H3K4Me3 in WT and Mll1+/2 mice. The
beads at the center of the granulomas are represented
by the dashed circles. (H) Mll1 expression in T cell
subsets isolated from the spleen by FACS at 14 d post-
PPD immunization. Effector and memory cells were
isolated, as described in F. Naı̈ve cells were defined as
CD44loCD62L+. Expression of Mll1 in CD4+ effector
cells isolated from the lungs of PPD-immunized and
-challenged mice at 4 d postinjection. For all data,
n = 3–5 animals/experiment. *P , 0.05, as de-
termined by Student’s t test. Results are representative
of 3 independent experiments.
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We also assessed cell death during and after in vitro
stimulation with anti-CD3/anti-CD28 antibody by propidium
iodide staining (Supplemental Fig. 1C). We found no change in
cell death during primary stimulation (up to 120 h post-anti-
CD3/anti-CD28 stimulation). However, we did find an increase
in propidium iodide+ cells in cultures containing Mll1+/2 Th1
cells during the resting phase of the culture. These data
eliminate the possibility that the reduction in proliferation that
we observed at 120 h postactivation in Th1 cultures was a result of
an excess of cell death at late time points of activation.
To correlate proliferation with cytokine production, we labeled
CD4+ T cells with CFSE and cultured them in Th1 conditions. At
96 h postactivation, we stained these samples with anti-IFN-g and
anti-IL-12RB2. Analysis indicated that there were significantly less
Mll1+/2 IFN-g+ cells that had undergone 4 cell divisions. In
contrast, IFN-g2 Mll1+/2 T cells were more proliferative than
IFN-g2 WT cells, suggesting that only those cells producing IFN-g
cytokine were reduced in proliferative capacity (Fig. 3G). This
observation is important, as it will drive experiments (seen in Fig.
4B). For all experiments in which we measured IFN-g,
production was measured during the normal course of T cell
differentiation, driven by activation with anti-CD3/anti-CD28 in
the presence or absence of IL-12 and anti-IL-4.
As IFN-g was found at reduced levels in the lungs of Mll1+/2
mice and in Mll1+/2 T cell cultures, we assessed expression of
several factors associated with Th1 cell biology, including the
transcription factor T-bet and the cytokine receptor IL-12RB2,
a critical receptor for Th1 cell proliferation and function [38]. In
vitro, we observed a significant reduction in Tbx21 mRNA
expression at 96 h postactivation in Th1 cultures (data not
shown). We also observed a reduction in T-bet+ effector cells in
Mll1+/2 mice sensitized and challenged with PPD antigen (Fig.
3H). In addition, there was a reduction of IL-12RB2+ effector
cells in these mice (Fig. 3I). Taken together, these data suggest
that Mll1 is an important IL-12-driven Th1 proliferation that
occurs as a result of T cell receptor activation.
IL-12 causes STAT4-dependent Mll1 expression
It is well established that the IL-12/STAT4 pathway is critical to
the differentiation of Th1 cells [4, 10, 13, 39, 40]. To determine
Figure 2. Mll1+/2 CD4+ T cells cause altered
granuloma pathology in Rag22/2 mice. Quantifica-
tion of IFN-g protein (A) and Mll1 mRNA expression
(B) in the lungs of Rag22/2 mice receiving Mll1+/2
T cells after PPD bead challenge. (C and D) Average
granuloma size in Rag22/2 mice receiving a transfer
of Mll1+/2 CD4+ T cells following sensitization with
CFA/PPD and subsequent challenge with PPD-coated
beads. (E and F) Quantification of the number of
total CD4+ T cells and myeloid cells in the lung.
Myeloid cell populations were defined as in Fig. 1F.
*P # 0.0,1 as determined by Student’s t test; n = 3–5
animals/experiment. Results are representative of 3
independent experiments.
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whether Mll1 is a target of the STAT4 signal transduction
pathway, we assessed the ability of IL-12-dependent STAT4 to
alter Mll1 expression in vitro. We initially observed an increase in
Mll1 gene expression at 48–72 h postactivation by use of anti-CD3
antibody. This increase in expression only occurred in cells
cultured in the presence of IL-12 and was reduced significantly
when Th1 cells were incubated with the JAK inhibitor tofacitinib
[41] (Fig. 4A). To characterize further the role of IL-12 in up-
regulation of Mll1, we developed a flow cytometry assay to assess
Mll1 protein levels by use of cells deficient inMll1 (Supplemental
Fig. 2A). We used this assay to assess the amount of Mll1 protein
induced in response to IL-12 (Fig. 4B and Supplemental Fig. 2B).
Consistent with the reduced expression of Mll1 that we observed
in effector cells (Fig. 1H), we found that the number of Mll1+
cells was highest at 24 h postactivation (Supplemental Fig. 2B)
and subsequently decreased over time, correlating with an
increase in cellular activation. As we had observed a decrease in
IFN-g+ cells in Mll1+/2 mice, we also assessed Mll1 expression in
conjunction with expression of IFN-g. We found that the peak of
Mll1 expression occurred in IFN-g+ cells at 72 h postactivation
with the addition of 10–25 ng/ml IL-12 (Fig. 4B). As IL-12
increased Mll1 expression in IFN-g+ T cells, we hypothesized that
the Mll1 gene was a target of the JAK/STAT pathway. To
determine if the IL-12 signaling pathway was directly responsible
for increasing Mll1 transcription, we activated T cells from
Stat42/2 mice under Th1 conditions and assessed expression of
Mll1 at 72 h postactivation by EDU incorporation and expression
of IFN-g. Although the total number of cells incorporating EDU
was not different between Stat42/2 cells and controls (Supple-
mental Fig. 2C), we found a significant reduction in Mll1+ EDU+
cells in Stat42/2 mice and cells treated with tofacitinib (Fig.
4C–E). Figure 4D demonstrates that Mll1 expression in T cells is
associated with those cells that incorporated high levels of EDU,
indicating rapid proliferation. We also observed a reduction in
Mll1+ IFN-g+ cells in these same cultures (Fig. 4F and G).
Figure 4F demonstrates that Mll1 expression is associated with
IFN-g production. For these experiments, cells were analyzed at
96 h postactivation with anti-CD3/anti-CD28 in the presence of
rIL-12 and anti-IL-4.
We then investigated the relationship between Mll1 expression
and STAT4 by use of a previously published data set, in which
ChIP-seq was performed on WT and Stat42/2 Th1 cells by use of
an antibody against STAT4 [42], again with use of a 96 h time
point. We identified 2 peaks within the Mll1 gene with significant
fold enrichment over that observed in Stat42/2 cells (Fig. 4H).
We searched within these peaks for potential STAT4-binding sites
[4] and found 3 separate sites within the large peak and a single,
conserved binding site within the small, intergenic peak. With
the focus on these potential binding sites, we found that STAT4
was bound to the promoter of the Mll1 gene at significantly
higher levels than found in Th0 cells (Fig. 4I), at 96 h post-CD3
stimulation under Th1 conditions. These results were significant
Figure 3. Mll1+/2 Th1 cells have reduced
proliferative capacity and have reduced ex-
pression of CCND3. (A) Assessment of pro-
liferation of WT and Mll1+/2 T cells under Th0
and Th1 conditions by [3H]thymidine uptake.
*P# 0.01, as determined by 1-way ANOVA. (B)
Depiction of the ratio of T cells proliferating in
the presence (Th1) vs. the absence (Th0) of
IL-12. This ratio is shown for WT and Mll1+/2
cells at the indicated time points. (C)
Proliferation of CD4+ T cells in vivo after
transfer into Rag22/2 mice during PPD chal-
lenge, as determined by EDU incorporation
and surface staining for total CD4+ T cells.
*P # 0.03, as determined by Student’s t test.
(D) Quantification of expression of Ccnd3, as
determined by qPCR after in vitro activation.
**P # 0.0001, as determined by 1-way ANOVA.
(E) Expression of Ccnd3 in lung-effector CD4
cells from PPD-immunized mice isolated as
described in Fig. 1G. *P , 0.05, as determined
by Student’s t test. (F) Determination of the
number of Ccnd3+ cells in cultures of WT and
Mll1+/2 T cells cultured under Th1 conditions,
as measured by flow cytometry. *P # 0.01, as
determined by 1-way ANOVA. (G) Intracellular
staining for IFN-g in CFSE-labeled cultures of
WT and Mll1+/2 cells activated under Th1
conditions. We observed a significant decrease
in CD4 IFN-g+ cells at 96 h postactivation. The
data also depict the percent of IFN-g+ and IFN-g2 cell populations undergoing multiple cell divisions in WT and Mll1+/2 cells. *P # 0.0001, as
determined by 2-way ANOVA. (H and I) Flow cytometric assessment of T-bet and IL-12RB2 protein levels on CD4+ effector cells in vivo, 4 d post-PPD
bead challenge. Effector cells were analyzed as CD44hi CD62Llo. *P , 0.03, as determined by Student’s t test. In vitro experiments were performed 3
times with the pooled cells of 2–3 animals for each replicate. In vivo experiments were done with n = 3–5 animals/group and repeated twice.
Schaller et al. Mll1 regulates IL-12-dependent Th1 gene expression
www.jleukbio.org Volume 98, October 2015 Journal of Leukocyte Biology 607
Figure 4. STAT4 binds to the Mll1 promoter. (A) PCR data assessing the levels of Mll1 in T cells cultured under normal Th0 or Th1 conditions or Th1
conditions with the addition of 1 mM of the JAK inhibitor tofacitinab (CP690,550). *P # 0.05, as determined by 1-way ANOVA. (B) Assessment of Mll1+
expression in IFN-g+ cells in response to increasing doses of rIL-12. *P# 0.01, as determined by 2-way ANOVA. (C) The number of Mll1+ cells in WT and
Stat42/2 cells and WT cells treated with the JAK inhibitor CP690,550. (D) Flow diagrams depicting the relationship between Mll1 expression and
(continued on next page)
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within the large peak at the beginning of the gene. In mice, all
STAT4 binding was reduced when Th1 cells were exposed to
tofacitinab. In humans,⅓ binding sites displayed reduced STAT4
binding upon exposure to this drug. These sites were specific to
STAT4, as performing ChIP with antibodies to STAT1, STAT3,
and STAT5 demonstrated no significant change in binding to the
promoter of Mll1 in Th1 cells compared with Th0 controls (data
not shown). To ascertain the specificity of our antibody, we
assessed binding in a known STAT4-binding site within the
promoter of the Il2 locus [43] and found amplification similar to
that observed in the Mll1 gene (Supplemental Fig. 2D and E).
We did not observe significant binding to confirmed STAT6-
binding sites in humans [44] or mice [45] (Supplemental Fig. 2D
and E). These data indicate a conserved up-regulation of Mll1 in
T cells that is mediated by IL-12 and STAT4 signaling. Taken
together, these data present evidence that STAT4 regulates the
transcription of Mll1 in human and mouse Th1 cells.
Increased H3K4Me3 and Mll1 binding within the Ccnd3
promoter under Th1 conditions
To determine if the genes we had found to be down-regulated in
Mll1+/2 Th1 cells were regulated directly by MLL1 binding to
the promoter region, we performed ChIP for the presence of
the H3K4Me3 mark and the C-terminal end of MLL1 on the
promoter of Il12rb2, Ccnd3, Tbx21, and Ifng at 96 h postactivation.
In all cases, we found an increase in H3K4Me3 at the promoters
of these genes in Th1 cells compared with Th0 cells, indicating
that these genes were activated. However, we only observed
a significant increase in MLL1 protein binding to the Ccnd3
promoter under Th1 conditions. Within the Ccnd3 promoter,
MLL1 binding correlated with H3K4Me3, indicating that this
gene is a direct target of MLL1 (Fig. 5). Although there was
a trend toward increased binding of MLL1 on other genes, this
trend did not reach significance for any of the indicated genes.
These data confirm the importance of MLL1 protein in
regulating the Th1 response by demonstrating direct and
consistent binding of MLL1 to Ccnd3, a target gene with reduced
expression in Mll1+/2 Th1 cells.
Mll1 is essential for the Th1 recall response
Previous research has demonstrated that Mll1+/2 T cells are
unable to convert to memory cells during a Th2 response [25].
As we observed increased cell death during the resting phase of
our Th1 cultures (Supplemental Fig. 1C and E) and as our in
vivo model demonstrated a deficiency in generating Th1
memory in Mll1+/2 mice (as demonstrated by a reduced PPD
recall response after sensitization), we further characterized the
role of the Mll1 gene and protein in human and mouse recall
responses. We observed a reduced amount of IFN-g produced
by Mll1+/2 Th1 cells after a period of rest and restimulation, as
detailed in Materials and Methods (Fig. 6A). In addition, Mll1+/2
Th1 cells that had been rested and restimulated did not
proliferate as well as WT cells (Fig. 6B). As we had already
observed decreased proliferation of CD4+ T cells in response to
PPD in vivo (Fig. 3D), we also wanted to determine if these
CD4+ T cells were the source of reduced IFN-g production
proliferation, as determined by incorporation of the nucleotide analog EDU. (E) Analysis of data in (D). (F) Flow diagrams depicting the relationship
between Mll1 expression and IFN-g. (G) Analysis of data in (F). (C, E, and G) *P # 0.01, as determined by 1-way ANOVA. (H) A depiction of the ChIP-
seq data generated by Wei et al. [42], focused on the Mll1 gene with regions of interest circled. (I) ChIP assay to determine if STAT4 binds to the Mll1
promoter in human and mouse Th1 cells. This assay was also done in the presence of 1 mM of the JAK inhibitor CP690,550. The dashed lines represent
the background level of detection in tubes immunoprecipitated with control Ig and are averaged among the 3 different conditions (Th0, Th1, and
Th1 + CP690,550) for each primer set. *P , 0.05 by 1-way ANOVA. Experiments that use murine cells were performed 3 times with the pooled cells of
3–5 animals for each replicate. Human data were generated by pooling experiments from 2 normal, healthy donors. Mouse cells were analyzed at
96 h postactivation, and human cells were analyzed at 144 h postactivation.
Figure 5. MLL1 binds to genes critical to Th1 cell differentiation. ChIP assay to quantify H3K4Me3 modifications and MLL1 binding to the promoters of
Tbx21, Ifng, IL12RB2, and Ccnd3 in murine Th0 and Th1 cells. TSS, Transcription start site. Negative numbers on the abscissa represent kilobases
upstream of the TSS. Data are pooled from 3 independent experiments performed with 1.0 3 107 pooled cells from 3 to 5 animals for each replicate.
*P # 0.05 by 1-way ANOVA.
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during PPD challenge in our mouse model. Thus, we isolated
CD4+ T cells from the draining lymph nodes of Mll1+/2
-sensitized and -challenged mice and cocultured these cells with
WT BMDCs in the presence of PPD antigen. Analysis of these
samples revealed significantly reduced IFN-g protein produc-
tion in cultures containing Mll1+/2 T cells (Fig. 6C).
To test the relevance of MLL1 in the human immune system,
we measured T cell proliferation and cytokine secretion induced
by tetanus toxoid in donors that had received a tetanus vaccine.
In humans, vaccination with tetanus toxoid produces a robust
Th1 memory response. To determine the importance of the
MLL1 protein in this memory response, we used a specific
inhibitor of the menin/MLL1 complex (MI-2-2) [34]. We found
that this inhibitor had no effect on the viability of CD4+ T cells up
to a 15 mM dose. We first observed a significant increase in
proliferation and IFN-g production in cultures pulsed with
tetanus toxoid compared with cultures containing no antigen. In
addition, increasing doses of MI-2-2 caused a reduction in T cell
proliferation and IFN-g production (Fig. 6D). These data
indicate that the interaction of menin with Mll family members is
important in driving the proliferation and cytokine production
associated with the human Th1 memory response.
DISCUSSION
We have demonstrated that the Mll1 gene is critical to Th1
differentiation in humans and mice. In mice, Mll1+/2 T cells
have a significant reduction in several factors associated with
Th1 biology, including IFN-g production, expression of T-bet
and IL-12RB2, and a decrease in the proliferative capacity of
Th1 cells. Our data show that an intact IL-12 signaling pathway
via STAT4 is important for proper Mll1 expression in Th1 cells
in humans and mice. Analysis of a dose-response experiment
revealed that although Mll1 decreases in all CD4+ cells activated
with anti-CD3, the presence of IL-12 increases Mll1 levels in
IFN-g+ cells. This specific up-regulation may allow for a rapid
proliferation of IFN-g+ effector cells to mediate an immune
response. Given that Mll1 is up-regulated by the STAT4
pathway, it is likely that other cytokines that signal through
STAT4, including IL-23, also up-regulate the expression of Mll1.
However, this possibility has not been formally tested.
Our results are in contrast to a previous report that Mll1+/2
T cells exhibited no change in Th1 skewing characterized by
early IFN-g production in vitro [25]. Our discovery of the crucial
role of Mll1 in the Th1 response occurred because of the
significant changes in pathology observed in our in vivo experi-
ments. The previous cited study examined the in vitro Th1
response by use of PMA and ionomycin to elicit IFN-g pro-
duction. We believe that studying the antigen-driven Th1
response was critical to our discovery of the crucial role ofMll1 in
this response, as PMA/ionomycin treatment of Mll1+/2 Th1 cells
also resulted in no difference in IFN-g production in our system
(data not shown).
The transition of naı̈ve T cells to memory cells requires an
intermediate effector phase, in which high-affinity T cell clones
rapidly expand in response to antigenic stimulation. As the
response resolves, the majority of these effector cells dies off,
Figure 6. Mll1 is essential for the T cell
recall response. (A) IFN-g production by
Mll1+/2 CD4+ T cells in vitro after 5 d of
activation and 3 d of rest, followed by an
additional 48 h of stimulation with anti-
CD3/anti-CD28. *P # 0.03 by Student’s
t test. (B) Proliferation of Mll1+/2 T cells in
the same conditions as in (A). *P # 0.03 by
Student’s t test. (C) IFN-g production from
CD4+ T cells isolated from the lungs of
PPD-sensitized and -challenged mice that
were then cocultured with BMDCs pulsed
with PPD for 48 h. **P # 0.001 by
Student’s t test. (D) Assessment of pro-
liferation and IFN-g production during the
tetanus toxoid recall response when
cocultures of T cells and monocyte-derived
DCs from the same donor were incubated
with the Mll1/menin inhibitor MI-2-2 for
5 d in the presence of tetanus toxoid. All
comparisons in (D) are made by use of the
DMSO control. *P , 0.05 by Student’s t test
compared with the 15 mM dose of inhibitor.
Culture supernatants were analyzed by
bioplex (A and C) or standard sandwich
ELISA (D). Proliferation was measured by
pulsing with [3H]thymidine on day 4 of
culture and measuring uptake over an 18 h
period. (A–C) Data are pooled from 3
independent experiments with the pooled
cells of 2–3 animals for each replicate.
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leaving a small pool of memory cells to respond the next time the
antigen is encountered [46]. Much of our data indicate that Mll1
is essential for proper Th1 cell-effector function. These data
include a reduction of effector CD4 T cells in Mll1+/2 mice in
response to PPD immunization and challenge, a reduction in
proliferation of Mll1+/2 effector cells in vitro, and an increase
in Mll1+IFN-g+ cells starting at 72 h postactivation during in vitro
differentiation. However, our data also indicate that as T cells
become activated, Mll1 expression is reduced (Fig. 1H and
Supplemental Fig. 2B). We conclude from these data that
although Mll1 expression is reduced during T cell activation
within the total population, it is increased in those cells that
produce IFN-g, thus providing these cytokine-producing cells
with a proliferative advantage, perhaps by increased expression
of Ccnd3. As previous studies and our own data in Fig. 6
demonstrate that Mll1 is involved in the memory response, it is
possible that the expression of Mll1 during the effector phase is
a requirement for a specific T cell to differentiate fully into
a memory cell.
Although a number of cyclin genes and cyclin-dependent
kinase inhibitors are expressed in T cells activated via anti-CD3/
anti-CD28 antibody stimulation, we specifically identified that
increased Mll1 expression is linked to proper expression of
Ccnd3 expression in CD4 T cells. Ccnd3 is a particularly
important gene for T cells, as Ccnd32/2 mice have normal
development except for a decrease in thymocyte and peripheral
T cell numbers [47]. Under normal conditions, T cells in the
periphery up-regulate Ccnd3 expression in response to IL-12 and
IL-2 [48–50]. In Mll1+/2 T cells, proliferation was only affected
under Th1 conditions, in which IL-12 was present (Fig. 3A and
B). Addition of exogenous IL-2 only partially corrected this
defect in proliferation (Fig. 3C). Therefore, we hypothesized
that the IL-12/STAT4/MLL1 pathway plays a unique role in
T cell proliferation. As evidence of this, we have demonstrated
that IL-12 signaling caused significant and unique H3K4Me3
modifications in the promoter region of the Ccnd3 locus that are
not present in cells activated with anti-CD3/anti-CD28 antibody
alone (Fig. 5). These modifications correlate with the binding of
MLL1 to the same promoter regions as those with H3K4Me3
modifications. Out of the genes that we examined that are
essential for the Th1 response, this correlation between MLL1
binding and H3K4Me3 modifications was significant only for
Ccnd3. However, we did observe a trend of MLL1 binding to the
promoter of Tbx21 and IL12RB2, 2 other genes associated with
the Th1 response. Consistent with previous research regarding
the regulation of gene transcription, we observed MLL1 binding
and H3K4Me3 modifications at sites 3–4 kb distal to the
transcription start site of the Ccnd3 gene. It has been
demonstrated that chromatin modifications at enhancer
regions, distal to transcription start sites or gene promoters, can
control cell-specific gene expression [51], a result consistent
with our observations on the Ccnd3 gene.
Our data demonstrate that removing the JAK component of
the JAK/STAT pathway results in reduced STAT4 binding to the
Mll1 promoter. These results suggest that inhibiting a JAK/STAT
pathway in T cells can alter the epigenetic process that
determines T cell phenotype. These data were confirmed by the
reduction of proliferating and cytokine-producing cells
expressing MLL1 in Stat42/2 mice. Furthermore, our data
demonstrate, for the first time, that a specific cytokine pathway
regulates MLL1 transcription in T cells in humans and mice. The
presence of a STAT-binding site in the intragenic region of Mll1
is consistent with previous findings that binding sites for these
transcription factors can occur in places other than the promoter
of the gene [52]. Although the exact role of intergenic
transcription factor-binding sites is unknown, it is associated with
a number of processes, including T cell differentiation and
proliferation [53, 54]. A recent study has suggested that STAT
proteins can alter enhancer regions by increasing H3K4Me1
modifications within the chromatin [15]. The STAT4-binding
site within the Mll1 gene may be one of these regions. It is likely
that STAT4 and other factors regulate the expression of Mll1 in
instances where rapid, nonhomeostatic cell proliferation is
required. As evidence of this, Mll1+/2 mice do not have any
alterations in hematopoiesis under normal circumstances [55].
Furthermore, this same study demonstrated that hematopoietic
cells with no functional copies of the Mll1 gene were able to
reconstitute an irradiated mouse when WT cells were absent.
These data demonstrate that homeostatic proliferation is un-
altered when Mll1 is nonfunctional. These findings further
suggest that the MLL1 protein complex may be a novel target for
immune disorders mediated by T cell responses.
The end result of Mll1 haploinsufficiency was altered
pathology in an antigen-driven, granulomatous response. We
observed a significant increase in granuloma size within the lungs
of Mll1+/2 mice. The observed pathology was accompanied by an
increase in neutrophils within the granuloma, without an
increase in IL-17 production. As this phenotype was recapitulated
in Rag22/2 mice receiving Mll1+/2 CD4+ T cell transfer (Fig. 2),
the altered phenotype is a result of defects in the Mll1+/2 CD4+
T cells. It has previously been reported that IFN-g signaling can
decrease the number of neutrophils generated from the bone
marrow via a suppressor of cytokine signaling 3-dependent
mechanism [56]. We also observed increases in IL-1, CXCL1, and
CXCL2 in the in the lungs of Mll1+/2 mice and RAG22/2 mice
receiving Mll1+/2 T cells (data not shown). We believe these
increases are responsible for neutrophil recruitment. In a model
of experimental autoimmune encephalomyelitis, IFN-g-deficient
mice had increased levels of the chemokine CXCL2 [57], thus
suggesting that reduction in IFN-g during an immune response
can cause aberrant expression of chemokines. Taken together
with our data, we believe that the change in pathology
observed in Mll1+/2 mice or Rag22/2 mice receiving Mll1+/2
T cells is solely a result of the reduced production of IFN-g by
these Mll1+/2 T cells.
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